Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine

被引:207
作者
Ahmed, Shabbir [1 ]
Zhou, Zhan [1 ]
Zhou, Jie [1 ]
Chen, Shu-Qing [1 ,2 ]
机构
[1] Zhejiang Univ, Dept Precis Med & Biopharmaceut, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China
[2] Zhejiang Calif Int NanoSyst Inst, Int Ctr Precis Med, Hangzhou 310058, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Drug transporters; Genetic polymorphism; Pharmacogenomics; Phase-I drug-metabolizing enzymes; Precision medicine;
D O I
10.1016/j.gpb.2016.03.008
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enables the evaluation of some specific genetic variants responsible for an individual's particular drug response. In this article, we review the contributions of genetic polymorphisms to major individual variations in drug pharmacotherapy, focusing specifically on the pharmacogenomics of phase-I drug metabolizing enzymes and transporters. Substantial frequency differences in key variants of drug metabolizing enzymes and transporters, as well as their possible functional consequences, have also been discussed across geographic regions. The current effort illustrates the common presence of variability in drug responses among individuals and across all geographic regions. This information will aid health-care professionals in prescribing the most appropriate treatment aimed at achieving the best possible beneficial outcomes while avoiding unwanted effects for a particular patient.
引用
收藏
页码:298 / 313
页数:16
相关论文
共 180 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]  
Akhondzadeh Shahin, 2014, Avicenna Journal of Medical Biotechnology, V6, P191
[3]   CLINICAL TRIAL OF ADJUNCTIVE CELECOXIB TREATMENT IN PATIENTS WITH MAJOR DEPRESSION: A DOUBLE BLIND AND PLACEBO CONTROLLED TRIAL [J].
Akhondzadeh, Shahin ;
Jafari, Sara ;
Raisi, Firoozeh ;
Nasehi, Abbas Ali ;
Ghoreishi, Aboulfazl ;
Salehi, Bahman ;
Mohebbi-Rasa, Soodeh ;
Raznahan, Maedeh ;
Kamalipour, Abbas .
DEPRESSION AND ANXIETY, 2009, 26 (07) :607-611
[4]  
Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
[5]  
[Anonymous], 2013, THESIS
[6]  
AOYAMA T, 1989, J BIOL CHEM, V264, P10388
[7]  
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[8]   Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran [J].
Azarpira, Negar ;
Namazi, Soha ;
Hendijani, Fatemeh ;
Banan, Maryam ;
Darai, Masumeh .
PHARMACOLOGICAL REPORTS, 2010, 62 (04) :740-746
[9]  
Borges J.B., 2015, Journal of Pharmacogenomics Pharmacoproteomics, V6, P1
[10]   Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment [J].
Borges, Silvana ;
Desta, Zeruesenay ;
Li, Lang ;
Skaar, Todd C. ;
Ward, Bryan A. ;
Nguyen, Anne ;
Jin, Yan ;
Storniolo, Anna Maria ;
Nikoloff, D. Michele ;
Wu, Lin ;
Hillman, Grant ;
Hayes, Daniel F. ;
Stearns, Vered ;
Flockhart, David A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :61-74